The Effectiveness of Shoulder Terminal Sensory Articular Nerve Radiofrequency Ablation for Non-surgical Refractory Shoulder Pain Due to Rotator Cuff Pathology and Osteoarthritis; A Prospective Pilot Study

Status: Recruiting
Location: See all (3) locations...
Study Type: Observational
SUMMARY

Through this prospective, single-arm cohort pilot study, we plan to explore the safety and effectiveness of Shoulder Radiofrequency Ablation (SRFA) in patients with non-operative chronic shoulder pain due to shoulder osteoarthritis with or without rotator cuff tears.

Eligibility
Participation Requirements
Sex: All
Minimum Age: 50
Healthy Volunteers: f
View:

• ≥50 years old capable of understanding and providing consent in English, and capable of complying with the outcome instruments used

• ≥3 months of shoulder pain refractory to conventional treatment (i.e., physiotherapy, medication, steroid injections)

• Persistent shoulder pain ≥ 4/10 in intensity on a 7-day average

• Shoulder pain refractory to conventional treatment (i.e., physical therapy, oral analgesics, steroid injection)

• Prior consultation with a board-certified orthopedic shoulder surgeon, deemed a non-surgical candidate for the primary diagnosis of glenohumeral joint pain +/- rotator cuff pain

• ≥80% pain relief for at least 30 minutes after a single fluoroscopically-guided block of the sensory branches of the SN, AN, and LPN with 0.5 mL of lidocaine at each nerve

• Scheduled for procedure of interest

Locations
United States
Utah
University of Utah Farmington Health Center
RECRUITING
Farmington
University of Utah Orthopaedic Center
RECRUITING
Salt Lake City
University of Utah South Jordan Health Center
RECRUITING
South Jordan
Contact Information
Primary
Amanda Cooper, PhD
amanda.cooper@utah.edu
985-516-2225
Backup
Taylor Burnham, DO
taylor.burnham@hsc.utah.edu
801-587-5488
Time Frame
Start Date: 2024-02-07
Estimated Completion Date: 2025-02
Participants
Target number of participants: 10
Related Therapeutic Areas
Sponsors
Leads: University of Utah

This content was sourced from clinicaltrials.gov